ATE529435T1 - Agonisten und antagonisten der rezeptoren des insulin und des igf-1 - Google Patents

Agonisten und antagonisten der rezeptoren des insulin und des igf-1

Info

Publication number
ATE529435T1
ATE529435T1 AT00918510T AT00918510T ATE529435T1 AT E529435 T1 ATE529435 T1 AT E529435T1 AT 00918510 T AT00918510 T AT 00918510T AT 00918510 T AT00918510 T AT 00918510T AT E529435 T1 ATE529435 T1 AT E529435T1
Authority
AT
Austria
Prior art keywords
insulin
agonists
antagonists
peptides
receptors
Prior art date
Application number
AT00918510T
Other languages
German (de)
English (en)
Inventor
James Beasley
Arthur Blume
Lauge Schaeffer
Renuka Pillutla
Jakob Brandt
Renee Brissette
Jane Spetzler
Weiqing Cheng
Soeren Oestergaard
Wlodek Mandecki
Per Hansen
Mark Ravera
Ku-Chuan Hsiao
Original Assignee
Dgi Biotechnologies L L C
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dgi Biotechnologies L L C, Novo Nordisk As filed Critical Dgi Biotechnologies L L C
Application granted granted Critical
Publication of ATE529435T1 publication Critical patent/ATE529435T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00918510T 2000-03-29 2000-03-29 Agonisten und antagonisten der rezeptoren des insulin und des igf-1 ATE529435T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008528 WO2001072771A2 (en) 2000-03-29 2000-03-29 Insulin and igf-1 receptor agonists and antagonists

Publications (1)

Publication Number Publication Date
ATE529435T1 true ATE529435T1 (de) 2011-11-15

Family

ID=21741219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918510T ATE529435T1 (de) 2000-03-29 2000-03-29 Agonisten und antagonisten der rezeptoren des insulin und des igf-1

Country Status (6)

Country Link
EP (2) EP1383793B1 (enExample)
JP (1) JP2004512010A (enExample)
AT (1) ATE529435T1 (enExample)
AU (1) AU2000239309A1 (enExample)
CA (1) CA2402780A1 (enExample)
WO (1) WO2001072771A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
CA2439735A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
EP2281841A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US7659362B2 (en) * 2006-05-30 2010-02-09 Academia Sinica Metal-binding motif compositions and methods
WO2008133961A2 (en) 2007-04-24 2008-11-06 Antyra Inc. Igf-1r binding proteins and antagonists
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
JP2014156401A (ja) * 2011-05-25 2014-08-28 Hoya Corp Ｉｇｆ−１ｒ結合性ペプチド
CN111377773A (zh) * 2020-04-16 2020-07-07 山东省现代中药研究院有限公司 一种含内生菌的花生用海藻复合微生物有机肥

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
DE4432943A1 (de) * 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
JPH11506722A (ja) * 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
RU2078769C1 (ru) * 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
WO1997046683A2 (en) * 1996-06-07 1997-12-11 Genetics Institute, Inc. Polynucleotides encoding secreted proteins
JP2002512685A (ja) * 1997-01-15 2002-04-23 テリック・インコーポレイテッド インスリン受容体活性のモジュレーター
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US7020563B1 (en) * 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
AU2321999A (en) * 1998-01-16 1999-08-02 Genzyme Corporation Adenoviral vectors with modified capsid proteins
WO2000006717A2 (en) * 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein

Also Published As

Publication number Publication date
EP1383793A2 (en) 2004-01-28
CA2402780A1 (en) 2001-10-04
WO2001072771A3 (en) 2003-12-04
WO2001072771A2 (en) 2001-10-04
EP2368902A3 (en) 2011-12-21
JP2004512010A (ja) 2004-04-22
AU2000239309A1 (en) 2001-10-08
EP1383793B1 (en) 2011-10-19
EP2368902A2 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
AU2000239309A1 (en) Insulin and igf-1 receptor agonists and antagonists
EP1496935A4 (en) AGONISTS AND ANTAGONISTS OF INSULIN RECEPTOR AND IGF-1
PT2241575E (pt) Polipéptidos de fusão que contêm o igf-1 e utilizações terapêuticas desses polipéptidos
Mogil et al. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family
MA31242B1 (fr) Co-agonistes des recepteurs du glucagon/glp-1
DE60335216D1 (de) Adiponektin-rezeptor und dafür kodierendes gen
Kinney et al. Structure–function analysis of urotensin II and its use in the construction of a ligand–receptor working model
ATE353918T1 (de) Zyklische peptide als agonisten für den melanocortin-4-rezeptor
DE602005016917D1 (de) Fgf-21-fusionsproteine
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
DK0972020T3 (da) Agonistmolekyler rettet imod insulinlignende vækstfaktorer
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
GB2286398A (en) Human metabotropic glutamate receptors,nucleic acids encoding same and uses thereof
WO2002072780A3 (en) Igf antagonist peptides
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
DE69836638D1 (de) Peptidanaloga abgeleitet vom tumornekrose-faktor-rezeptor
DK1265605T3 (da) Farmaceutiske sammensætninger omfattende peptidmimetisk, cyklisk beta-drejningsforbindelse
DK1282437T3 (da) Behandling af brusklidelser
ATE241616T1 (de) Abgewandelte aminosäureamide als cgrp antagonisten
EP1361872A4 (en) NEW LYSOPHOSPHIC ACID RECEPTOR AGONISTS AND ANTAGONISTS
IL181311A (en) Variants of neoblastin polypeptide, dimers, conjugates, and fusion proteins that include them, pharmacological compounds based on them, nucleic acids encoding them, and vectors - expression including said nucleic acids, cells containing said vectors, methods for making and using said polypeptides
DE69720207D1 (de) Peptide mit spezifischer affinität für pacap typ 1 rezeptoren
WO2005009358A3 (en) Conformationally constrained parathyroid hormone (pth) analogs
ES2150495T3 (es) Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
TW200635919A (en) Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties